Generate Biomedicines Quarterly Income Statement
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.34+0.35 (+2.50%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Generate Biomedicines revenue and earnings
In the quarter ended Jun 30, 2026, Generate Biomedicines generated $6.3 million in revenue. Generate Biomedicines reported a net loss of $67.3 million. Operating margin was -1134.2%.
Diluted earnings per share came in at -$0.52.
Summary generated from market data by MetaCap's automated system. Methodology
Generate Biomedicines income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Revenue | 6.31M | 7.22M | 10.13M | 8.82M |
| Revenue growth (YoY) | — | — | — | — |
| Operating Expenses | 77.93M | 71.34M | 70.28M | 56.97M |
| Research & Development | 64.33M | 57.81M | 59.73M | 46.83M |
| Operating Income | -71.61M | -64.11M | -60.15M | -48.15M |
| Interest Expense | 155.00K | 182.00K | 307.00K | 368.00K |
| Other Income (Expense) | 4.41M | 2.43M | 3.45M | 3.90M |
| Pretax Income | -67.20M | -61.69M | -56.70M | -44.26M |
| Income Tax | 53.00K | 28.00K | 44.00K | 56.00K |
| Net Income | -67.25M | -61.45M | -52.43M | -41.69M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -0.52 | -1.07 | -1.94 | -1.62 |
| EPS (Diluted) | -0.52 | -1.07 | -1.94 | -1.62 |
| Shares Outstanding (Basic) | 128.24M | 64.87M | 33.00M | 32.79M |
| Shares Outstanding (Diluted) | 128.24M | 64.87M | 33.00M | 32.79M |
| EBITDA | -68.41M | -60.84M | -56.85M | -44.74M |
| Operating Margin | -1134.21% | -887.49% | -593.78% | -546.09% |
| Net Margin | -1065.17% | -850.58% | -517.56% | -472.73% |
This table shows 4 quarterly periods of Generate Biomedicines's income statement, from Q2 2026 back to Q? 2025, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow GENB's reporting calendar. What is a income statement?